BioCardia, Inc.

BioCardia, Inc. issued a letter to shareholders outlining its business strategy, top priorities, and business development opportunities. A key focus is the planned submission for approval of its CardiAMP Cell Therapy for ischemic heart failure to Japan's PMDA by Q4 2026, targeting an initial 20,000 patients with potential reimbursement of $124,000 per procedure. The company is also advancing its CardiAMP HF II Trial in the US and pursuing partnerships for its Helix delivery system and allogeneic MSC therapy platforms. These milestones are expected to create compelling opportunities for value creation.

BioCardia, Inc. announced its strategic priorities, focusing on the submission for approval of CardiAMP Cell Therapy for ischemic heart failure of reduced ejection fraction (HFrEF) to Japan's PMDA by the end of 2026. This initiative is considered a transformative business opportunity, with potential reimbursement of $124,000 per procedure for an initial target of 20,000 patients. The company also continues enrollment for the CardiAMP HF II Trial in the US and is pursuing strategic partnerships for its Helix/Heart3D delivery platform and allogeneic MSC therapies, supported by a recent capital raise.

BioCardia, Inc. announced it has regained compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement. The company previously received a delisting notice and was granted an extension until October 7, 2026, to comply. Through an "At The Market" offering, BioCardia sold 4,004,330 shares between April 1 and June 5, 2026, generating $4.9 million in net proceeds, which it believes has restored its stockholders' equity above the threshold.

BioCardia, Inc. announced the sale of 3,509,604 shares at an average price of $1.279 per share, generating approximately $4.49 million in net proceeds. This capital raise is expected to extend the company's cash runway into the first quarter of 2027, beyond the anticipated Japan PMDA submission. The company also noted that the full exercise of currently outstanding warrants could further extend the cash runway well beyond PMDA approval and into initial commercial sales.

BioCardia, Inc. announced it raised approximately $4.4 million through an "At The Market" (ATM) offering. The company sold 3,509,604 shares at an average price of $1.279 per share on June 5, 2026. These net proceeds are expected to extend BioCardia's cash runway into the first quarter of 2027, covering operations beyond the anticipated Japan PMDA submission for CardiAMP HF in Q4 2026. Further exercise of outstanding warrants could extend the runway even further, potentially into first commercial sales.

BioCardia, Inc. announced that the FDA confirmed its ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for its CardiAMP Cell Therapy System. This system is designed for treating ischemic heart failure of reduced ejection fraction (HFrEF). PMA is the most rigorous device marketing application, and this confirmation is a significant step towards market clearance. The company plans to complete the US trial for PMA and seek regulatory approval in Japan.

BioCardia announced receipt of FDA minutes confirming its CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for its CardiAMP Cell Therapy System for ischemic heart failure of reduced ejection fraction (HFrEF). The FDA previously indicated a preference for two trials for approval but considers the system safe. CEO Peter Altman emphasized the patient need and the strength of existing data. Japan's PMDA also indicated that clinical results from three completed trials likely provide sufficient evidence for approval.

BioCardia, Inc. announced that Japan's Pharmaceutical and Medical Device Agency (PMDA) supports the submission for regulatory approval of its CardiAMP® cell therapy for ischemic heart failure of reduced ejection fraction (HFrEF). The PMDA confirmed alignment on remaining questions and found the trial's positive outcomes credible, noting an urgent unmet clinical need. The therapy targets an estimated 20,000 of 300,000 eligible patients in Japan, with submission anticipated in Q4 2026. BioCardia plans for post-marketing studies and collaboration with Japanese academic societies.

BioCardia announced positive preliminary open-label cohort results from its CardiAMP Cell Therapy in Chronic Myocardial Ischemia (CMI) Trial at Euro PCR. The minimally invasive procedure was well tolerated with no major adverse cardiac events. Patients demonstrated significant improvements, including an average increase of 179 seconds in exercise tolerance and an 82% reduction in angina episodes, which persisted for up to two years.

BioCardia, Inc. reported a net loss of $2.26 million for the first quarter of 2026, an improvement from $2.71 million in the same period last year. However, the company's cash and cash equivalents significantly declined to $951,000 as of March 31, 2026, leading management to issue a going concern warning, stating current funds are insufficient beyond June 2026. Despite financial challenges, BioCardia made progress in its clinical programs, with Japan's PMDA indicating sufficient evidence for market clearance of CardiAMP Cell Therapy and the US FDA confirming the PMA pathway while recommending continuation of the CardiAMP HF II trial.